Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I/II trial of SCTB41 Injection in advanced malignant solid tumors
CTR20243305Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2024
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB41 in Non-hematologic malignancy, sponsored by Sinocelltech Group Limited. Started Oct 2024; status: active.
02
Drugs
SCTB41
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20243305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243305.